<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition</h2>
    <div class="badge">2025-09-09T12:10:32+00:00</div>
    <ul>
      <li>Novartis will pay $48.00 per share in cash at closing, a 59% premium to Tourmaline’s September 8 closing price and 127% above its 60-day volume-weighted average.</li>
<li>The deal is expected to close in the fourth quarter of 2025.</li>
<li>If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.</li>
<li>In April, Novartis acquired Regulus Therapeutics for an initial payment of $7.00 per share in cash or $0.8 billion.</li>
<li>Other Deals In 2025 To Bolster Heart and Kidney Drug Portfolio Earlier in 2025, Novartis agreed to acquire Anthos Therapeutics Inc.</li>
<li>for an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.</li>
<li>(NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Novartis%20To%20Expand%20Heart%20Drug%20Portfolio%20With%20%241.4%20Billion%20Tourmaline%20Bio%20Acquisition%0A%E2%80%A2%20Novartis%20will%20pay%20%2448.00%20per%20share%20in%20cash%20at%20closing%2C%20a%2059%25%20premium%20to%20Tourmaline%E2%80%99s%20September%208%20closing%20price%20and%20127%25%20above%20its%2060-day%20volume-weighted%20average.%0A%E2%80%A2%20The%20deal%20is%20expected%20to%20close%20in%20the%20fourth%20quarter%20of%202025.%0A%E2%80%A2%20If%20the%20milestone%20is%20achieved%2C%20total%20consideration%2C%20including%20the%20CVR%2C%20would%20be%20approximately%20%241.7%20billion.%0A%E2%80%A2%20In%20April%2C%20Novartis%20acquired%20Regulus%20Therapeutics%20for%20an%20initial%20payment%20of%20%247.00%20per%20share%20in%20cash%20or%20%240.8%20billion.%0A%E2%80%A2%20Other%20Deals%20In%202025%20To%20Bolster%20Heart%20and%20Kidney%20Drug%20Portfolio%20Earlier%20in%202025%2C%20Novartis%20agreed%20to%20acquire%20Anthos%20Therapeutics%20Inc.%0A%E2%80%A2%20for%20an%20upfront%20payment%20of%20%24925%20million%20and%20potential%20additional%20payments%20of%20up%20to%20%242.15%20billion%20upon%20achieving%20specified%20regulatory%20and%20sales%20milestones.%0A%E2%80%A2%20%28NASDAQ%3ATRML%29%20shares%20surged%20Tuesday%20after%20Novartis%20AG%20%28NYSE%3ANVS%29%20announced%20a%20%241.4%20billion%20acquisition%20of%20the%20U.S.-based%20biotech%2C%20strengthening%20the%20Swiss%20drugmaker%E2%80%99s%20pipeline%20of%20cardiovascular%20and%20kidney%20treatments.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fnovartis-to-expand-heart-drug-portfolio-with-1-4-billion-tourmaline-bio-acquisit%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/novartis-expand-heart-drug-portfolio-121032541.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>